胰高血糖素样肽-1受体激动剂与新血管性年龄相关性黄斑变性的风险
这项基于人群的回顾性队列研究纳入加拿大安大略省139002例匹配的糖尿病患者,其中46334例暴露于GLP-1 RA、92668例未暴露。暴露组新发nAMD发生率为0.2%,未暴露组为0.1%;校正后HR为2.21(95%CI 1.65-2.96)。作者认为GLP-1 RA使用与nAMD发生风险约2倍升高相关。
要点
- 糖尿病患者使用GLP-1 RA与nAMD发生风险升高相关,校正后HR为2.21(95%CI 1.65-2.96)。
- 暴露组nAMD发生率为0.2%,未暴露组为0.1%,绝对差异为0.1%。
- 作者指出需进一步研究阐明确切病理生理机制及GLP-1 RA获益与风险的权衡。
核心结论
- 在糖尿病患者中,使用GLP-1 RA与新发nAMD风险约2倍升高相关,校正后HR为2.21(95%CI 1.65-2.96)。
- 作者指出需进一步研究阐明确切病理生理机制,并理解GLP-1 RA获益与风险之间的权衡。
研究设计与样本
- 基于人群的回顾性队列研究,研究时间为2020年1月至2023年11月,随访3年,数据分析时间为2024年8月至2024年10月。
- 数据来自加拿大安大略省由临床评价科学研究所收集的全面行政健康和人口学数据,背景为全民公共医疗体系。
- 纳入标准为年龄66岁及以上、诊断为糖尿病且初次糖尿病诊断后至少随访12个月的患者。
- 排除标准为安大略省健康保险计划或安大略省药物福利数据不完整者,以及GLP-1 RA暴露不足6个月者。
- 在1119517例符合条件的患者中,构建了1:2匹配队列共139002例,包括46334例暴露于GLP-1 RA的患者和92668例未暴露的匹配患者;采用与任何类型AMD相关的全身合并症和社会经济地位计算倾向评分。
主要发现
- 在139002例匹配患者中,平均(SD)年龄为66.2(7.5)岁,64775例(46.6%)为女性。
- 暴露队列nAMD发生率高于未暴露队列:暴露组0.2% vs 未暴露组0.1%,差异为0.1%。
- Cox比例风险模型估计暴露于GLP-1 RA的患者发生nAMD的风险比为:粗HR 2.11(95%CI 1.58-2.82),校正后HR 2.21(95%CI 1.65-2.96)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出需进一步研究阐明确切病理生理机制,并理解GLP-1 RA获益与风险之间的权衡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are extensively used in treating diabetes and obesity, yet little is known about the long-term ocular effects of systemic prolonged exposure. OBJECTIVE: To evaluate the risk of developing neovascular age-related macular degeneration (nAMD) associated with the use of GLP-1 RAs in patients with diabetes. DESIGN, SETTING, AND PARTICIPANTS: This population-based, retrospective cohort study was conducted from January 2020 to November 2023, with a follow-up period of 3 years. Data analysis was performed from August 2024 to October 2024. The investigators used comprehensive administrative health and demographic data from patients in Ontario, Canada, which were collected by the Institute for Clinical Evaluative Sciences in the context of a universal public health care system. Inclusion criteria were patients aged 66 years or older with a diagnosis of diabetes and a minimum follow-up period of 12 months following initial diabetes diagnosis. Patients with incomplete Ontario Health Insurance Plan or Ontario Drug Benefit data or patients exposed to GLP-1 RA for less than 6 months were excluded. Of 1 119 517 eligible patients, a 1:2 matched cohort of 139 002 patients was created, including 46 334 patients who were exposed to GLP-1 RAs and 92 668 unexposed matched patients. Systemic comorbidities that were associated with any kind of AMD and socioeconomic status were used to calculate propensity scores. EXPOSURE: GLP-1 RA use for 6 months or longer. MAIN OUTCOMES AND MEASURES: The primary outcome was the incidence and time to event of nAMD during the follow-up period. RESULTS: Among 139 002 matched patients, mean (SD) patient age was 66.2 (7.5) years, and 64 775 patients (46.6%) were women. The incidence of nAMD was higher among the exposed cohort than among the unexposed cohort. Cox proportional hazard models, both unadjusted (crude) and adjusted, estimated hazard ratios for nAMD development of greater than 2.0 among patients exposed to GLP-1 RAs (exposed, 0.2% vs unexposed, 0.1%; difference, 0.1%; crude: HR, 2.11; 95% CI, 1.58-2.82; adjusted: HR, 2.21; 95% CI, 1.65-2.96). CONCLUSIONS AND RELEVANCE: In this cohort study, the use of GLP-1 RAs among patients with diabetes was associated with a 2-fold higher risk of incident nAMD development than among similar patients with diabetes who did not receive a GLP-1 RA. Further research is needed to elucidate the exact pathophysiological mechanisms involved and to understand the trade-offs between the benefits and risks of GLP-1 RAs.
引用
- Shor R, Mihalache A, Noori A, et al. Glucagon-Like Peptide-1 Receptor Agonists and Risk of Neovascular Age-Related Macular Degeneration. JAMA Ophthalmol. 2025. PMID: 40471562. doi:10.1001/jamaophthalmol.2025.1455
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。